← Human Trials & Peer-Reviewed Studies
Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial
Plain-language guide to PMID 22742720 (2012): crossover randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 14 men.
Key Facts
- PMID
- 22742720
- Journal
- BMC nephrology
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Bleskestad IH et al. (5 authors)
- DOI
- 10.1186/1471-2369-13-49
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.
The use of active vitamin D and phosphate binders as recommended in international guidelines, may affect the level of FGF23 and thereby clinical outcome.
European Clinical Trial Database (EudraCT) 2010-020415-36 and Clinical Trials.gov NCT01231438.
Who Took Part
The abstract describes 14 men taking part.
The age groups tagged for this paper are older adults, both men and women.
Seven women and 14 men were included, mean age 65.6 ± 12.2 years.
They were randomized in a 1:1 ratio to receive one of two treatment sequences.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
The men were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.
Each person switched between Parathyroid Hormone (PTH 1-84) and the comparison at some point, usually with a gap in between.
Group-2 (the sevelamer carbonate-alphacalcidol group): vice versa.
Nineteen patients completed the study.
What Was Measured
The use of active vitamin D and phosphate binders as recommended in international guidelines, may affect the level of FGF23 and thereby clinical outcome.
PubMed files the paper under topics including Biomarkers, Chelating Agents, Fibroblast Growth Factor-23, Fibroblast Growth Factors, Hyperparathyroidism, Secondary, Parathyroid Hormone and Polyamines.
What This Means in Plain Language
The paper is a randomized and crossover study of Parathyroid Hormone (PTH 1-84) in 14 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2012 (BMC nephrology), a journal based in England.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.